التفاصيل البيبلوغرافية
| العنوان: |
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. |
| المؤلفون: |
Yee, Andrew J., Raje, Noopur S. |
| المصدر: |
Clinical Interventions in Aging; 2012, Vol. 7, p331-338, 8p |
| مصطلحات موضوعية: |
CANCER treatment complications, BONE diseases, MONOCLONAL antibodies, HORMONE antagonists, BONE densitometry, TARGETED drug delivery, DRUG side effects, DISEASE risk factors |
| مستخلص: |
Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Interventions in Aging is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder